Savient Pharmaceuticals (NASDAQ: SVNT) today announced that its Board of Directors has engaged Citigroup Corporate and Investment Banking to explore strategic alternatives for its wholly-owned subsidiary, Rosemont Pharmaceuticals, including the potential spin out or sale of the business. Rosemont is a leading developer, manufacturer and marketer of high quality oral liquid medicines in the United Kingdom.
